Hypomagnesemia is a common complication of aminoglycoside therapy

Surg Gynecol Obstet. 1984 Jun;158(6):561-5.


Normal therapeutic dosages of aminoglycosides can cause hypomagnesemia in more than one-third of patients. Hypomagnesemia occurs early in therapy, results in renal Mg++ wasting and may produce hypocalcemia and hypokalemia. Patients who are NPO, eating poorly or not receiving supplemental Mg++ are at high risk for hypomagnesemia. Hypomagnesemia, hypocalcemia and hypokalemia respond to Mg++ replacement therapy. We recommend serial monitoring of serum Mg++ levels in patients receiving aminoglycoside therapy.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aminoglycosides / adverse effects
  • Anti-Bacterial Agents / adverse effects*
  • Female
  • Humans
  • Hypocalcemia / chemically induced
  • Hypokalemia / chemically induced
  • Infections / drug therapy
  • Magnesium / urine
  • Magnesium Deficiency / blood
  • Magnesium Deficiency / chemically induced*
  • Male
  • Middle Aged
  • Prospective Studies
  • Radioimmunoassay
  • Risk
  • Spectrophotometry, Atomic
  • Time Factors


  • Aminoglycosides
  • Anti-Bacterial Agents
  • Magnesium